HER2+ breast cancer
Oncology · 2006–2025
31decisions
11medicines
13carried consumer input
57individual submissions
Every decision
| Medicine | Meeting | Outcome | Consumer input |
|---|---|---|---|
| pertuzumab Neoadjuvant treatment of patients with HER2-positive, locally advanced, inflammatory or early stage (>2 cm in diameter or node positive) early breast cancer,… | Mar 2025 | Recommended with restriction | input received |
| tucatinib Metastatic (Stage IV) HER2-positive breast cancer in patients who have received two prior lines of HER2-directed therapy or who have progressed on trastuzumab… | Nov 2025 | Recommended with restriction | 5 individuals |
| trastuzumab deruxtecan Treatment of HER2-positive metastatic breast cancer in adult patients who have progressed following a prior HER2-directed therapy in the metastatic setting or… | Jul 2022 | Recommended with restriction | 4 individuals Breast Cancer Network Australia · Medical Oncology Group |
| tucatinib Metastatic (Stage IV) HER2-positive breast cancer in patients who have progressed following at least two prior HER2-directed regimens for metastatic disease… | Mar 2021 | Not recommended | 2 individuals Cancer Network Australia · Medical Oncology Group |
| trastuzumab Treatment of metastatic (Stage IV) HER2 positive breast cancer, metastatic (Stage IV) HER2 positive adenocarcinoma of the stomach or gastro-oesophageal… | Nov 2021 | Recommended with restriction | none received |
| pertuzumab Neoadjuvant treatment in patients with HER2-positive locally advanced, inflammatory or early stage (≥2 cm in diameter or node positive) early breast cancer, in… | Mar 2020 | Not recommended | input received Breast Cancer Network Australia |
| trastuzumab HER2-positive early, locally advanced and metastatic breast cancer, and HER2-positive metastatic gastric cancer. | Jul 2019 | Recommended | none received |
| trastuzumab HER2-positive early breast cancer, locally advanced breast cancer, metastatic breast cancer, and advanced gastric cancer. | Jul 2019 | Recommended | none received |
| neratinib Extended adjuvant treatment of adult patients with HER2-positive, hormone receptor positive early breast cancer who have completed prior adjuvant… | Mar 2019 | Not recommended | 3 individuals |
| pertuzumab Adjuvant treatment of human epidermal growth factor receptor-2 (HER2) positive, lymph node positive early breast cancer. | Mar 2019 | Not recommended | 1 individuals |
| trastuzumab HER2-positive early, locally advanced and metastatic breast cancer, and HER2-positive metastatic gastric cancer. | Mar 2019 | Recommended | none received |
| trastuzumab HER2-positive early, locally advanced and metastatic breast cancer, and HER2-positive metastatic gastric cancer. | Mar 2019 | Recommended | none received |
| neratinib Extended adjuvant treatment of adult patients with HER2-positive, hormone receptor positive, early breast cancer who have completed prior adjuvant… | Nov 2019 | Not recommended | 37 individuals |
| trastuzumab emtansine Adjuvant treatment of patients with HER2-positive early breast cancer who have residual disease after pre-operative systemic treatment that included… | Nov 2019 | Recommended | input received |
| trastuzumab HER2-positive early, locally advanced and metastatic breast cancer, and HER2-positive metastatic gastric cancer. | Nov 2019 | Recommended with restriction | none received |
| pertuzumab Human epidermal growth factor 2 (HER2) positive, lymph node positive, early breast cancer in the adjuvant setting. | Jul 2018 | Not recommended | 1 individuals |
| trastuzumab Treatment of HER2-positive early breast cancer, locally advanced breast cancer, and metastatic breast cancer. The subcutaneous formulation offers an… | Jul 2015 | Recommended with restriction | input received |
| nab-paclitaxel Treatment of HER2-positive metastatic breast cancer in combination with trastuzumab. | Nov 2015 | Not recommended | input received |
| pertuzumab HER2-positive metastatic breast cancer in combination with trastuzumab and docetaxel for patients who have not received prior anti-HER2 therapy or chemotherapy… | Mar 2014 | Deferred | unclear |
| trastuzumab emtansine Treatment of HER2-positive metastatic breast cancer (stage IV) in patients who have received prior therapy with trastuzumab and a taxane, and whose disease has… | Mar 2014 | Deferred | unclear |
| trastuzumab; pertuzumab; trastuzumab emtansine Trastuzumab: first-line and second/later-line treatment of HER2-positive metastatic breast cancer. Pertuzumab: first-line treatment in combination with… | Nov 2014 | Recommended with restriction | 4 individuals |
| trastuzumab emtansine HER2-positive unresectable locally advanced or metastatic breast cancer (stage IV) who have received prior therapy with trastuzumab and a taxane and whose… | Jul 2013 | Not recommended | unclear |
| trastuzumab Initial and continuing treatment of HER2 positive early breast cancer (EBC) commencing concurrently with neoadjuvant chemotherapy; and initial and continuing… | Jul 2012 | Recommended with restriction | no section in document |
| pegfilgrastim Primary prophylaxis for chemotherapy-induced neutropenia in patients with breast cancer treated with docetaxel. | Mar 2008 | Not recommended | no section in document |
| trastuzumab Treatment of HER-2 positive metastatic breast cancer, either in combination with taxanes for first-line treatment or as monotherapy for patients who have… | Nov 2008 | Recommended | no section in document |
| lapatinib ditosylate monohydrate for use in combination with capecitabine, for the treatment of patients with advanced or metastatic breast cancer whose tumours overexpress HER2 (ErbB2) and… | Jul 2007 | Not recommended | no section in document |
| lapatinib ditosylate monohydrate Treatment of patients with advanced or metastatic breast cancer whose tumours overexpress HER2 (ErbB2) and who have received prior therapy including… | Jul 2007 | Not recommended | no section in document |
| lapatinib ditosylate Initial treatment of patients with HER2-positive metastatic breast cancer who have received prior therapy with an anthracycline and a taxane administered… | Nov 2007 | Recommended | no section in document |
| lapatinib ditosylate Metastatic HER2-positive breast cancer in patients who have received prior therapy with an anthracycline and a taxane, and whose disease progresses despite… | Nov 2007 | Not recommended | no section in document |
| trastuzumab Treatment of HER2 positive early breast cancer following surgery in association with chemotherapy. | Jul 2006 | Recommended with restriction | no section in document |
| trastuzumab Treatment of patients with HER2 positive early breast cancer (node-positive disease, or node-negative disease with primary tumour diameter >20 mm) following… | Jul 2006 | Recommended with restriction | no section in document |
Who spoke
Breast Cancer Network Australia · Medical Oncology Group · Cancer Network Australia
Conditions are classified by a language model from the indication text of each submission, so an individual label here can be wrong. Consumer input is read from the document's own consumer comments section: 13 of 21 decisions since 2014 carried some. Silence means no comment reached the committee through that facility, not that nobody was affected. More on how this was built.